BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic diseases, has scheduled its second quarter 2025 financial results conference call for Tuesday, August 5, 2025, at 4:30 pm ET. The company will release its financial results and business updates after market close on the same day.
Investors and interested parties can access the live webcast through BridgeBio's investor relations website. A replay will be available for 30 days following the event.
BridgeBio Pharma (Nasdaq: BBIO), un'azienda biofarmaceutica specializzata in malattie genetiche, ha programmato la sua conferenza telefonica sui risultati finanziari del secondo trimestre 2025 per marted矛 5 agosto 2025, alle 16:30 ET. La societ脿 pubblicher脿 i risultati finanziari e gli aggiornamenti aziendali dopo la chiusura del mercato lo stesso giorno.
Investitori e soggetti interessati potranno seguire la diretta streaming tramite il sito web delle relazioni con gli investitori di BridgeBio. La registrazione sar脿 disponibile per 30 giorni dopo l鈥檈vento.
BridgeBio Pharma (Nasdaq: BBIO), una compa帽铆a biofarmac茅utica especializada en enfermedades gen茅ticas, ha programado su conferencia telef贸nica de resultados financieros del segundo trimestre de 2025 para el martes 5 de agosto de 2025, a las 4:30 pm ET. La empresa publicar谩 sus resultados financieros y actualizaciones comerciales despu茅s del cierre del mercado ese mismo d铆a.
Los inversores y partes interesadas pueden acceder a la transmisi贸n en vivo a trav茅s del sitio web de relaciones con inversores de BridgeBio. La repetici贸n estar谩 disponible durante 30 d铆as despu茅s del evento.
BridgeBio Pharma (雮橃姢雼�: BBIO)電� 鞙犾爠 歆堩櫂鞚� 鞝勲鞙茧 頃橂姅 氚旍澊鞓れ牅鞎� 須岇偓搿�, 2025雲� 2攵勱赴 鞛 鞁れ爜 旎嵓霟办姢 旖�鞚� 2025雲� 8鞗� 5鞚� 頇旍殧鞚� 鞓ろ泟 4鞁� 30攵�(霃欕秬鞁滉皠)鞐� 臧滌禍頃� 鞓堨爼鞛呺媹雼�. 須岇偓電� 臧欖潃 雮� 鞁滌灔 毵堦皭 頉� 鞛 鞁れ爜 氚� 靷梾 鞐呺嵃鞚错姼毳� 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
韴瀽鞛� 氚� 甏�鞁� 鞛堧姅 攵勲摛鞚� BridgeBio 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞁れ嫓臧� 鞗轨簮鞀ろ姼鞐� 鞝戩啀頃� 靾� 鞛堨姷雼堧嫟. 頄夓偓臧� 雭濍倻 頉� 30鞚� 霃欖晥 雼れ嫓氤搓赴 靹滊箘鞀る弰 鞝滉车霅╇媹雼�.
BridgeBio Pharma (Nasdaq : BBIO), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans les maladies g茅n茅tiques, a programm茅 sa conf茅rence t茅l茅phonique sur les r茅sultats financiers du deuxi猫me trimestre 2025 pour le mardi 5 ao没t 2025 脿 16h30 ET. L'entreprise publiera ses r茅sultats financiers et ses mises 脿 jour commerciales apr猫s la cl么ture du march茅 le m锚me jour.
Les investisseurs et les parties int茅ress茅es pourront acc茅der 脿 la diffusion en direct via le site web des relations investisseurs de BridgeBio. Une rediffusion sera disponible pendant 30 jours apr猫s l'茅v茅nement.
BridgeBio Pharma (Nasdaq: BBIO), ein biopharmazeutisches Unternehmen, das sich auf genetische Erkrankungen spezialisiert hat, hat seine Telefonkonferenz zu den Finanzergebnissen des zweiten Quartals 2025 蹿眉谤 Dienstag, den 5. August 2025, um 16:30 Uhr ET angesetzt. Das Unternehmen wird seine Finanzergebnisse und Gesch盲ftsaktualisierungen am selben Tag nach B枚rsenschluss ver枚ffentlichen.
Investoren und Interessierte k枚nnen den Live-Webcast 眉ber die Investor-Relations-Website von BridgeBio verfolgen. Eine Aufzeichnung steht 30 Tage nach der Veranstaltung zur Verf眉gung.
- None.
- None.
PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (鈥淏ridgeBio鈥� or the 鈥淐ompany鈥�), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.
To access the live webcast of BridgeBio鈥檚 presentation, please visit the 鈥淓vents & Presentations鈥� page within the Investors section of the BridgeBio website at . A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
Participants may access the webcast by registering online using the following link, .
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio鈥檚 pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit and follow us on , , and .
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
听听
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
FAQ
When will BridgeBio (BBIO) report Q2 2025 earnings?
How can I access BridgeBio's Q2 2025 earnings call?
How long will BridgeBio's Q2 2025 earnings call replay be available?
What is BridgeBio's stock symbol?
